Flexion Therapeutics to Start FX006 Phase 3 Pivotal Trial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Flexion Therapeutics to Start FX006 Phase 3 Pivotal Trial in 2014; Following FDA Meeting, Development Plan Advanced by One Year

- Company to Host Conference Call Tomorrow, September 4, 2014 at 8:30 a.m. EST, During Which Management Will Discuss Updated Timing and Plans

BURLINGTON, Mass., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Based on a recent meeting with the U.S. Food and Drug Administration (FDA) to review the clinical development program for Flexion's lead drug candidate FX006, Flexion Therapeutics, Inc. (Nasdaq: FLXN ), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies, today announced plans to initiate a pivotal Phase 3 clinical trial for FX006 in late 2014. FX006 is a steroid, triamcinolone acetonide (TCA), formulated for sustained-release, which is delivered by intra-articular ("IA" or "in the joint") injection in patients with osteoarthritis (OA) pain of the knee. The company believes the new timing will allow Phase 3 development to be completed by the end of 2015, a year earlier than previously planned.

In a recent meeting with the FDA, the agency communicated that it will consider the company's ongoing placebo-controlled Phase 2b confirmatory trial of FX006 as one of two key efficacy trials required for registration of a single-dose administration for FX006. In addition, the FDA provided guidance that a second placebo-controlled pivotal trial would be sufficient to support the filing of a new drug application (NDA). The FDA also communicated that the approval of FX006 for single-dose administration will not require data from a repeat-dose safety trial, which enabled the most significant change from the company's prior clinical development plan. As a result, the company has decided to advance the initiation of the Phase 3 trial of FX006 to late 2014, to remove the repeat-dose safety trial from its pre-approval plans, and to develop and file the repeat-dose safety data in a supplemental new drug application (sNDA) after approval and launch of FX006 for single-dose administration.

"We view the recent guidance from the FDA and our new clinical development plan for FX006 as transformative for our company. This plan reduces both technical and regulatory risk and allows us to accelerate our commercial launch by a year," said Michael D. Clayman, M.D., President and CEO of Flexion. "In addition, our plan to evaluate FX006 compared to immediate-release TCA is intended to complement the clinically meaningful and statistically significant data demonstrating superior pain relief of FX006 observed in our initial Phase 2b dose-ranging trial and to support a commercial advantage in the launch of the drug."       

The Phase 3 trial will be an international, multi-center, randomized, blinded, single-dose study in 462 patients with OA of the knee. It will have three arms that include a 40 mg dose of FX006, placebo and a 40 mg dose of immediate-release TCA. The primary objective of the trial will be to provide the second pivotal efficacy dataset against placebo at 12 weeks for an NDA submission. In addition, the trial will provide a key comparative dataset against the current standard of care, immediate-release TCA.

Conference Call

Flexion's management team will host a conference call and webcast at 8:30 a.m. EST tomorrow, September 4, 2014, to provide an update on the new clinical development plan for FX006. The dial-in number for the conference call is toll-free (855) 770-0022 for domestic participants and (908) 982-4677 for international participants. A live webcast of the conference call can also be accessed through the "Investors" tab on the Flexion Therapeutics website at www.flexiontherapeutics.com . A webcast replay will be available online after the call.

About FX006

FX006 is a first-in-class injectable, sustained-release, IA steroid in development for patients with moderate to severe OA pain. FX006 was specifically designed to address the limitations of current IA therapies by providing long-lasting, local analgesia while avoiding systemic side effects. To date, over 300 patients have been exposed to FX006. In a completed Phase 2b dose-ranging clinical trial, FX006 demonstrated clinically meaningful and significantly better pain relief compared to the current injectable standard of care, TCA. In two Phase 2a synovial fluid PK studies, a single IA injection of FX006 demonstrated therapeutic concentrations of drug in joint fluid for at least 12 weeks. FX006 is currently being studied in a pivotal Phase 2b confirmatory clinical trial to further identify a safe and well-tolerated dose of FX006 that demonstrates superior pain relief to placebo. 

About Osteoarthritis of the Knee

OA, also referred to as degenerative joint disease, is the most common joint disease in the United States, affecting 27 million Americans, with numbers expected to grow as a result of aging, obesity and sports injuries. With the U.S. population between the ages of 45 and 64 having grown 31.5 percent from 2000 through 2010 and accounting for 26.4 percent of the total population, changing demographics – as well as increasing obesity among this population – will likely contribute to a growing number of OA patients. In addition, knee injury is common, particularly amongst young athletes, and increases the risk of developing OA by more than fivefold. One in two Americans is expected to develop symptomatic knee OA, the most common form of OA, during their lifetime, according to the U.S. Centers for Disease Control and Prevention (CDC). Recent research estimates that the average age of physician-diagnosed knee OA has fallen by 16 years, from age 72 in the 1990s to age 56 in the 2010s. According to the same research, Americans between the ages of 35 and 84 in the early 2010s will account for approximately 6.5 million new cases of knee OA over the next decade.

About Flexion Therapeutics

Flexion is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies. The company is currently advancing a portfolio of injectable drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapy. The company's lead program, FX006, is an intra-articular sustained release steroid in development for patients with moderate to severe OA pain. The company also has two additional product candidates, FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor for end-stage OA patients.

Forward-Looking Statements

Statements in this press release regarding matters that are not historical facts, including statements relating to the future of Flexion, its ongoing development of its product candidates, the initiation of a Phase 3 trial for FX006, the potential timing for completing Phase 3 development for FX006, the anticipated requirements for filing an NDA and obtaining regulatory approval for FX006, initiation of a repeat-dose safety trial and anticipated clinical and other milestones (including the timing of such milestones) are forward-looking statements. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks associated with the process of discovering, developing and obtaining regulatory approval for drugs that are safe and effective for use as human therapeutics, whether the company's patents will be held valid and enforceable, the fact that Flexion relies on third parties to manufacture and conduct the clinical trials of its product candidates, which could delay or limit their future development or regulatory approval, the possibility that future trial results may not be consistent with past results, the fact that Flexion will require additional capital, including prior to completing Phase 3 development of, filing for regulatory approval for, or commercializing, FX006 or any of its other product candidates and may be unable to obtain such additional capital in sufficient amounts or on terms acceptable to it, the fact that the FDA may change its guidance at any time or impose additional requirements, and other risks and uncertainties described in Flexion's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in Flexion's Annual Report on Form 10-K for the year ended December 31, 2013 and subsequent filings with the SEC. You are encouraged to read Flexion's filings with the SEC, available at www.sec.gov , for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this press release, and Flexion undertakes no obligation to update or revise any of the statements.

Media Contact Lisa Guiterman T: (301) 217-9353 Corporate Contact Lisa Davidson, MBA Vice President, Finance and Administration Flexion Therapeutics, Inc. T: 781-305-7765

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 55

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Better Life Science: Revolutionizing At-Home STI Testing

Updated Category News Views 98

Paving a New Path for STI Testing Accessibility The landscape of STI testing is undergoing a significant shift, and Better Life Science is at the helm with their innovative STD Hero at-home testing service. With a splash in the latest AVN report, they're turning heads in both the clinical world and in mainstream society. This ain't just about checking boxes in health...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 41

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
Local Bounti Expands: Acquires CEA Facilities

Updated Category News Views 37

Local Bounti's Strategic Acquisition Move Local Bounti's at it again, shaking up the indoor agriculture scene by snapping up some real estate from Revol Greens. We're talking 30 acres of primo certified-organic greenhouse space across Texas and Minnesota. And they’re picking these babies up right as they’re ready to grow, not like some flashy land grab. Digging into...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 97

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Surgical Tooth Extraction: When It’s Necessary

Updated Category News Views 42

Unpacking the Complexities of Tooth Extraction Ever wonder why some tooth extractions are a stroll in the park while others dive straight into surgical territory? It's all about positioning, condition, and what's lurking underneath. Thanks to Dr. Yadira Cardona-Rohena of Hamilton Mill Oral & Facial Surgery, we’ve got the lowdown. The Need for Skilled Surgical Techniques...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 31

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 223

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 32

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 185

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading

Top 5 Most Recently Viewed Articles

Key Insights into Rathbones Group Plc's Position Disclosure

Updated Category News Views 171

Understanding Disclosure Requirements in Financial Markets In the world of finance and investments, transparency is paramount. Investors and market participants must be aware of regulations surrounding disclosure, especially when significant interest in relevant securities occurs. Here, we delve into key details surrounding a recent public disclosure by Rathbones Group...

Continue Reading
Atkore Inc. Announces Quarterly Cash Dividend for Shareholders

Updated Category News Views 139

Atkore Inc. Announces Cash Dividend for Shareholders Atkore Inc. (NYSE: ATKR), a prominent manufacturer known for its extensive electrical products, has informed its investors about the declaration of a quarterly cash dividend. This announcement signifies the company's ongoing commitment to providing value to its shareholders. The dividend is set at $0.32 per share of...

Continue Reading
Innovating Home Textiles: How CiCLO® is Changing Luxury Fabrics

Updated Category News Views 248

Innovative Technologies in Home Textiles An innovative fiber design blending renewable and biodegradable materials is advancing comfort, longevity, and responsible performance in premium home and hospitality textiles. At Heimtextil 2026, Intrinsic Advanced Materials will showcase a new generation of luxury textiles that embody sustainable practices, collaborating with...

Continue Reading
Vegan Food Industry Set for Huge Growth: USD 55.88 Billion by 2034

Updated Category News Views 271

Overview of the Vegan Food Market Growth The global vegan food market is anticipated to witness significant growth, increasing from USD 20.22 billion to an impressive USD 55.88 billion by 2034. This remarkable shift, with a compound annual growth rate (CAGR) of 10.7% from 2025 to 2034, reflects the rising consumer demand for plant-based options. Consumer Trends Driving...

Continue Reading
BAOS Stock Hits New Heights with Investor Enthusiasm

Updated Category News Views 190

BAOS Stock Surges to 52-Week High In a remarkable display of market confidence, Baosheng Media Group Holdings Limited (BAOS) has achieved a significant milestone by reaching a 52-week high of $7.33 per share. This surge demonstrates the strong backing from investors and the company's solid financial standing. Company Valuation and Financial Health The micro-cap company,...

Continue Reading